entity

MAPK14/PRMT1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MAPK14/PRMT1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
1Hypotheses
1Analyses
1Outgoing
0Incoming
1Experiments
1Debates

No AI portrait yet

Outgoing (1)

TargetRelationTypeStr
neurodegenerationpromoted: p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methydisease0.61

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
p38α Inhibitor and PRMT1 Activator Combination to Restore Ph 0.895 neurodegeneration What is the therapeutic window between i

Mentioning Analyses (1)

Scientific analyses that reference this entity

What is the therapeutic window between insufficient and toxic levels of TDP-43 a

neurodegeneration | 2026-04-12 | 2 hypotheses Top: 0.895

Experiments (1)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
MAPK pathway inhibition by QTJD through butyrate mechanism exploratory Mycoplasma pneumoniae pneumoni 0.900 0.00 Mouse macrophages proposed N/A

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (1)

Multi-agent debates referencing this entity

The debate highlighted a critical dosing paradox where both hypo- and hypermethy

closed · Rounds: 4 · Score: 0.82 · 2026-04-12

Related Research

Hypotheses and analyses mentioning MAPK14/PRMT1 in their description or question text

No additional research found